;PMID: 6543484 ;source_file_1000.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..36] = [t:0..36] ;1)sentence:[e:42..116] = [t:42..116] ;2)section:[e:120..147] = [t:120..147] ;3)sentence:[e:151..401] = [t:151..401] ;4)sentence:[e:402..485] = [t:402..485] ;5)sentence:[e:486..653] = [t:486..653] ;6)sentence:[e:654..717] = [t:654..717] ;7)section:[e:721..765] = [t:721..765] ;section 0 Span:0..36 ;Acta Biochim Pol. 1984;31(4):409-19. (SEC (FRAG (NNP:[0..4] Acta) (NNP:[5..12] Biochim) (NNP:[13..16] Pol) (.:[16..17] .) (CD:[18..22] 1984) (::[22..26] ;31-LRB-) (CD:[26..28] 4-RRB-) (CD:[28..32] :409) (::[32..33] -) (CD:[33..35] 19) (.:[35..36] .))) ;sentence 1 Span:42..116 ;A study on the Prethcamide hydroxylation system in rat hepatic microsomes. ;[57..68]:substance:"Prethcamide" (SENT (NP-HLN (NP (DT:[42..43] A) (NN:[44..49] study)) (PP (IN:[50..52] on) (NP (NP (DT:[53..56] the) (NNP:[57..68] Prethcamide) (NN:[69..82] hydroxylation) (NN:[83..89] system)) (PP-LOC (IN:[90..92] in) (NP (NN:[93..96] rat) (JJ:[97..104] hepatic) (NNS:[105..115] microsomes))))) (.:[115..116] .))) ;section 2 Span:120..147 ;Szumilo T, Bryla P, Byra A. (SEC (FRAG (NNP:[120..127] Szumilo) (NNP:[128..129] T) (,:[129..130] ,) (NNP:[131..136] Bryla) (NNP:[137..138] P) (,:[138..139] ,) (NNP:[140..144] Byra) (NN:[145..147] A.))) ;sentence 3 Span:151..401 ;Ethyl butamide and propyl butamide, the active constituents of the analeptic ;drug named Prethcamide (Ciba-Geigy), undergo biotransformation to respective ;single metabolites in the presence of rat hepatic microsomes and the ;NADPH-generating system. ;[151..165]:substance:"Ethyl butamide" ;[170..185]:substance:"propyl butamide" ;[218..233]:substance:"analeptic drug" ;[240..251]:substance:"Prethcamide" ;[314..325]:substance:"metabolites" ;[377..382]:substance:"NADPH" (SENT (S (NP-SBJ (NP (NP (NN:[151..156] Ethyl) (NN:[157..165] butamide)) (CC:[166..169] and) (NP (NN:[170..176] propyl) (NN:[177..185] butamide))) (,:[185..186] ,) (NP (NP (DT:[187..190] the) (JJ:[191..197] active) (NNS:[198..210] constituents)) (PP (IN:[211..213] of) (NP (NP (DT:[214..217] the) (JJ:[218..227] analeptic) (NN:[229..233] drug)) (VP (VBN:[234..239] named) (NP (-NONE-:[239..239] *)) (NP (NNP:[240..251] Prethcamide) (PRN (-LRB-:[252..253] -LRB-) (NP (NNP:[253..257] Ciba) (HYPH:[257..258] -) (NNP:[258..263] Geigy)) (-RRB-:[263..264] -RRB-)))))))) (,:[264..265] ,) (VP (VBP:[266..273] undergo) (NP (NP (NN:[274..291] biotransformation)) (PP (TO:[292..294] to) (NP (JJ:[295..305] respective) (JJ:[307..313] single) (NNS:[314..325] metabolites)))) (PP (IN:[326..328] in) (NP (NP (DT:[329..332] the) (NN:[333..341] presence)) (PP (IN:[342..344] of) (NP (NP (NN:[345..348] rat) (JJ:[349..356] hepatic) (NNS:[357..367] microsomes)) (CC:[368..371] and) (NP (DT:[372..375] the) (ADJP (NN:[377..382] NADPH) (HYPH:[382..383] -) (VBG:[383..393] generating)) (NN:[394..400] system))))))) (.:[400..401] .))) ;sentence 4 Span:402..485 ;Spectral analysis showed that the metabolites were hydroxylated forms of the ;drug. ;[436..447]:substance:"metabolites" ;[480..484]:substance:"drug" (SENT (S (NP-SBJ (JJ:[402..410] Spectral) (NN:[411..419] analysis)) (VP (VBD:[420..426] showed) (SBAR (IN:[427..431] that) (S (NP-SBJ (DT:[432..435] the) (NNS:[436..447] metabolites)) (VP (VBD:[448..452] were) (NP-PRD (NP (VBN:[454..466] hydroxylated) (NNS:[467..472] forms)) (PP (IN:[473..475] of) (NP (DT:[476..479] the) (NN:[480..484] drug)))))))) (.:[484..485] .))) ;sentence 5 Span:486..653 ;The hydroxylation was stimulated by NADH and increased ionic strength, and ;inhibited by the known cytochrome P-450 inhibitors, e.g. SKF-525A, ;metyrapone, CO and KCN. ;[522..526]:substance:"NADH" ;[585..601]:cyp450:"cytochrome P-450" ;[603..613]:substance:"inhibitors" ;[620..628]:substance:"SKF-525A" ;[630..640]:substance:"metyrapone" ;[642..644]:substance:"CO" ;[649..652]:substance:"KCN" (SENT (S (NP-SBJ-1 (DT:[486..489] The) (NN:[490..503] hydroxylation)) (VP (VBD:[504..507] was) (VP (VP (VBN:[508..518] stimulated) (NP-1 (-NONE-:[518..518] *)) (PP (IN:[519..521] by) (NP-LGS (NP (NN:[522..526] NADH)) (CC:[527..530] and) (NP (VBN:[532..541] increased) (JJ:[542..547] ionic) (NN:[548..556] strength))))) (,:[556..557] ,) (CC:[558..561] and) (VP (VBN:[562..571] inhibited) (NP-1 (-NONE-:[571..571] *)) (PP (IN:[572..574] by) (NP-LGS (NP (DT:[575..578] the) (VBN:[579..584] known) (NML (NN:[585..595] cytochrome) (NN:[596..601] P-450)) (NNS:[603..613] inhibitors)) (,:[613..614] ,) (NP (ADVP (FW:[615..619] e.g.)) (NN:[620..628] SKF-525A) (,:[628..629] ,) (NN:[630..640] metyrapone) (,:[640..641] ,) (NN:[642..644] CO) (CC:[645..648] and) (NN:[649..652] KCN))))))) (.:[652..653] .))) ;sentence 6 Span:654..717 ;The drug formed type I binding spectrum with cytochrome P-450. ;[658..662]:substance:"drug" ;[700..716]:cyp450:"cytochrome P-450" (SENT (S (NP-SBJ (DT:[654..657] The) (NN:[658..662] drug)) (VP (VBD:[663..669] formed) (NP (NP (NML (NN:[670..674] type) (CD:[675..676] I)) (NN:[678..685] binding) (NN:[686..694] spectrum)) (PP (IN:[695..699] with) (NP (NN:[700..710] cytochrome) (NN:[711..716] P-450))))) (.:[716..717] .))) ;section 7 Span:721..765 ;PMID: 6543484 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[721..725] PMID) (::[725..726] :) (CD:[727..734] 6543484) (NN:[735..736] -LSB-) (NNP:[736..742] PubMed) (::[743..744] -) (NN:[745..752] indexed) (IN:[753..756] for) (NNP:[757..765] MEDLINE-RSB-)))